BP
TBPH icon

Ballentine Partners’s Theravance Biopharma TBPH Stock Holding History

Ballentine Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Hold
14,362
– – ﹤0.01% 911
2026
Q1 		$233K Hold
14,362
– – ﹤0.01% 857
2025
Q4 		$269K Sell
14,362
-26
-0.2% -$431 ﹤0.01% 764
2025
Q3 		$210K Buy
14,388
+73
+0.5% +$922 ﹤0.01% 889
2025
Q2 		$158K Buy
14,315
+1,221
+9% +$11.9K ﹤0.01% 907
2025
Q1 		$117K Hold
13,094
– – ﹤0.01% 849
2024
Q4 		$123K Buy
13,094
+246
+2% +$2.24K ﹤0.01% 823
2024
Q3 		$104K Buy
+12,848
New +$111K ﹤0.01% 801

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ballentine Partners's TBPH Position: Q2 2026 in Review

Ballentine Partners held its Theravance Biopharma (TBPH) position steady in Q2 2026 at 14,362 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #911.

Ballentine Partners first reported a position in TBPH in Q3 2024 and has held it in 8 quarters since. The position peaked at $269K in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Ballentine Partners held 14,362 shares of Theravance Biopharma worth $244K as of Q2 2026.
  • Ballentine Partners left its Theravance Biopharma share count unchanged in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #911 holding.
  • Ballentine Partners first reported a position in Theravance Biopharma in Q3 2024 and has held it in 8 quarters since.
  • Ballentine Partners's Theravance Biopharma position peaked at $269K in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.